HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: M200035-MCP200v1 1/11/876    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Glossary Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Smith, D. L. Articles by Whetton, A. D. Search for Related Content PubMed PubMed Citation Articles by Smith, D. L. Articles by Whetton, A. D. Social Bookmarking                      What's this?

Molecular & Cellular Proteomics 1:876-884, 2002.
© 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

---

Research

Changes in the Proteome Associated with the Action of Bcr-Abl Tyrosine Kinase Are Not Related to Transcriptional Regulation^*

Duncan L. Smith^,, Caroline A. Evans, Andrew Pierce, Simon J. Gaskell and Anthony D. Whetton^,¶

Leukaemia Research Fund Cellular Development Unit, Department of Biomolecular Sciences
Michael Barber Centre for Mass Spectrometry, Department of Chemistry, University of Manchester Institute of Science and Technology, Manchester M60 1QD, United Kingdom

Chronic myeloid leukemia (CML) is a hematopoietic stem cell disease, the hallmark of which is the Bcr-Abl protein tyrosine kinase (PTK). Without intervention the disease progresses from a benign chronic phase to a rapidly fatal blast crisis. To identify the molecular mechanisms underlying disease progression we used two-dimensional gel electrophoresis on a model we have previously described using the expression of a conditional mutant of Bcr-Abl PTK in a multipotent stem cell line, FDCP-Mix. Long term exposure of FDCP-Mix cells to Bcr-Abl mimics disease progression in CML. Four major differences were observed as a consequence of long term exposure to the Bcr-Abl PTK compared with cells exposed short term. The proteins were identified using matrix-assisted laser desorption ionization-time of flight mass spectrometry-generated peptide mass fingerprint data and liquid chromatography-tandem mass spectrometry-generated sequence information. Leukotriene A4 hydrolase, an enzyme known to be deregulated in CML, was found to be up-regulated. Annexin VI, vacuolar ATP synthase catalytic subunit A, and mortalin were found to be down-regulated. Poly(A) PCR cDNA analysis showed there was no correlation between the protein expression changes and mRNA levels. Western blot analysis also indicated no change in the levels of mortalin or leukotriene A4 hydrolase, indicating that post-translational events may modify protein content of the specific spots. Leukotriene B4 levels (product of leukotriene A4 hydrolase) were, however, reduced in cells exposed long term to Bcr-Abl activity. This study demonstrates the potential of proteomic analysis to define novel effects of oncogenes.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				S. Balabanov, A. Gontarewicz, P. Ziegler, U. Hartmann, W. Kammer, M. Copland, U. Brassat, M. Priemer, I. Hauber, T. Wilhelm, et al. Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABL-positive leukemias identified by a proteomics approach Blood, February 15, 2007; 109(4): 1701 - 1711. [Abstract] [Full Text] [PDF]

				I. M. Cristea, S. J. Gaskell, and A. D. Whetton Proteomics techniques and their application to hematology Blood, May 15, 2004; 103(10): 3624 - 3634. [Abstract] [Full Text] [PDF]

				C. A. Evans, R. Tonge, D. Blinco, A. Pierce, J. Shaw, Y. Lu, H. G. Hamzah, A. Gray, C. P. Downes, S. J. Gaskell, et al. Comparative proteomics of primitive hematopoietic cell populations reveals differences in expression of proteins regulating motility Blood, May 15, 2004; 103(10): 3751 - 3759. [Abstract] [Full Text] [PDF]